4E2 Stock Chart & Stats
€4.40
€0.20(4.76%)
At close: 4:00 PM EDT
€4.40
€0.20(4.76%)
Day’s Range― - ―
52-Week Range€1.13 - €6.50
Previous CloseN/A
Volume0.00
Average Volume (3M)79.00
Market Cap
€406.18M
Enterprise Value€559.91
Total Cash (Recent Filing)€217.73M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding106,669,846
10 Day Avg. Volume179
30 Day Avg. Volume79
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.34Price Target Upside180.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe strengthened cash position gives Relmada time to advance NDV-01 through Phase III without an immediate financing requirement. Funding visibility through 2029 supports sustained clinical execution and reduces near-term liquidity pressure while the company remains pre-commercial.
NDV-01 EfficacyStrong 12-month Phase II response durability provides meaningful clinical validation for NDV-01 and supports progression toward registrational development. If replicated, these results could strengthen the program’s differentiation and improve its prospects for regulatory and commercial success.
Regulatory And Clinical ReadinessFDA alignment and an established site network create a defined path toward Phase III execution rather than leaving the program dependent on an unstructured development plan. Prepared sites may help Relmada move efficiently once the IND and clinical material are ready.
Bears Say
Pre-commercial LossesRelmada has no product revenue to offset its development costs, leaving earnings dependent on future clinical and regulatory success. Persistent operating losses increase the time required to reach breakeven and keep the company exposed to capital needs before commercialization.
Negative Cash GenerationOngoing operating and free-cash-flow deficits show that Relmada currently consumes cash rather than funding its programs internally. Although burn has improved versus prior years, continued negative generation can reduce financial flexibility and eventually require additional external capital.
CMC-driven Timeline RiskThe remaining manufacturing and stability work makes regulatory timing dependent on successful CMC execution. A delayed IND would push back NDV-01’s Phase III start and extend the period before potential value inflection, while increasing exposure to further development spending.
Relmada Therapeutics News
4E2 FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was €1.13 and its highest was €6.50 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is €406.18M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 58 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -€0.095 earnings per share for the quarter, beating the consensus estimate of -€0.173 by €0.078.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 106,669,846 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -€0.095 in its last earnings report, beating expectations of -€0.173. Following the earnings report the stock price went up 1.322%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:4E2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.34 (180.51% Upside)
€12.34 (180.51% Upside)
Blogger Sentiment
Bullish
DE:4E2 Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
223.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
937.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
4E2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and execution-focused tone: Relmada reported a materially strengthened balance sheet (cash +134% YoY) with a cash runway into 2029, compelling 12-month Phase II efficacy and favorable safety for NDV-01, clear FDA-aligned registration pathways, an experienced new CBO, and engaged clinical sites. Key near-term risks center on manufacturing/CMC execution (GMP batch production and stability data), which shifted IND timing toward year-end 2026 and has increased R&D spend and operating cash use. On balance the company appears well-capitalized and positioned to advance registrational programs, but outcomes hinge on resolving manufacturing scale-up and timing.View all DE:4E2 earnings summaries4E2 Stock 12 Month Forecast
Average Price Target
€12.34
▲(180.51% Upside)